G01N 2333/52
Assays involving cytokines
G01N2333/52 (Assays involving cytokines) appears on 1,220 US grants and 2,664 published applications in this corpus.
Search patents in G01N- Granted patents
- 1,220
- Published applications
- 2,664
- Assignees
- 1,245
- Inventors
- 5,107
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 5 | 0 |
| 1998 | 12 | 0 |
| 1999 | 18 | 0 |
| 2000 | 13 | 0 |
| 2001 | 14 | 5 |
| 2002 | 9 | 25 |
| 2003 | 19 | 56 |
| 2004 | 10 | 37 |
| 2005 | 19 | 64 |
| 2006 | 12 | 41 |
| 2007 | 17 | 69 |
| 2008 | 18 | 56 |
| 2009 | 29 | 73 |
| 2010 | 35 | 99 |
| 2011 | 41 | 118 |
| 2012 | 47 | 113 |
| 2013 | 48 | 92 |
| 2014 | 46 | 109 |
| 2015 | 61 | 148 |
| 2016 | 55 | 174 |
| 2017 | 80 | 149 |
| 2018 | 86 | 142 |
| 2019 | 75 | 123 |
| 2020 | 86 | 146 |
| 2021 | 74 | 143 |
| 2022 | 66 | 149 |
| 2023 | 59 | 144 |
| 2024 | 56 | 143 |
| 2025 | 64 | 125 |
| 2026 | 40 | 121 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- G01N 2333/54Interleukins [il]Indexing code635
- G01N 2333/525Tumor necrosis factor [tnf]Indexing code229
- G01N 2333/555Interferons [ifn]Indexing code214
- G01N 2333/521ChemokinesIndexing code177
- G01N 2333/53Colony-stimulating factor [csf]Indexing code34
- G01N 2333/524Thrombopoietin, i.e. c-mpl ligandIndexing code0
Recent patents
- IFNβ as a pharmacodynamic marker in VSV-IFNβ-NIS oncolytic therapy6 Oct 2026US 12,754,182 B2Mayo Foundation for Medical Education and Research
- Drug-specific pharmacokinetic assay for IL-15 superagonist6 Oct 2026US 12,754,189 B2NantCell, Inc.
- Equine multiplex health information panel22 Sep 2026US 12,742,788 B1Boundless Diagnostics Inc
- Treatment of autoimmune liver disease15 Sep 2026US 12,736,544 B2The Governors of the University of Alberta
- Controlled release of antibodies to modulate cytokines8 Sep 2026US 12,729,237 B2Flow Pharma, Inc.
- Composition, methods and uses8 Oct 2026US 2026/0306509 A14E Therapeutics, Inc.
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Electrochemical biosensors, systems, and methods of use8 Oct 2026US 2026/0309671 A1
- Selective glucocorticoid receptor modifiers for treating impaired skin wound healing1 Oct 2026US 2026/0294918 A1Akribes Biomedical GmbH
- Anti il-11 antibody1 Oct 2026US 2026/0297176 A1
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Antibodies to human programmed death receptor PD-1454US 8,354,509 B2MSD Oss B.V. · 2013
- Protein detection via nanoreporters166US 9,714,937 B2NanoString Technologies, Inc. · 2017
- Antibodies to human programmed death receptor PD-1151US 8,900,587 B2Merck Sharp & Dohme Corp. · 2014
- Methods and apparatus for conducting multiple measurements on a sample125US 7,858,321 B2Meso Scale Technologies, LLC. · 2010